Nodality, Inc. Develops Disease-Associated PD-1 Assay System For Application In Immuno-oncology

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., presented today at the 26th EORTC-NCI-AACR Symposium (Barcelona, Spain) a newly-developed human cell-based system to quantitate PD-1 activity. Nodality’s Single Cell Network Profiling (SCNP) technology detected significant differences in PD-1+ T cell subset signaling when comparing samples from patients with chronic lymphocytic leukemia (CLL) and healthy donors. Specifically, the SCNP platform demonstrated PD-1+ T cells from CLL patients displayed dysfunctional signaling following modulation with the cytokines IL-2, IL-7 and IL-15 versus healthy donor cells. Further, the ability to quantify the effects of PD-1 modulation on T Cell Receptor (TCR) signaling through pancreatic ER kinase (pERK) in PD-1+ T cells was established.

Help employers find you! Check out all the jobs and post your resume.